Few naming conventions cause more confusion in peptide research than CJC-1295. Two related but distinct compounds share the name, and choosing the wrong one changes a study design fundamentally.
The Shared Backbone
Both versions start from the same idea: a GHRH(1-29) sequence — the fully active fragment also sold as Sermorelin — stabilized with four amino acid substitutions that resist enzymatic cleavage. This modified backbone is often called Mod GRF 1-29.
What DAC Changes
The Drug Affinity Complex is a chemical anchor that binds the peptide to circulating albumin, stretching its active life from minutes to days. CJC-1295 with DAC therefore produces sustained, flattened GHRH receptor stimulation — suited to research questions about continuous activation.
Why No DAC Exists
The No DAC version retains the stabilized backbone but clears quickly, preserving the pulsatile signaling pattern that mirrors natural GHRH release. That makes it the standard partner in combination designs — our CJC-1295 (No DAC) / Ipamorelin blend pairs it with a ghrelin-receptor agonist for dual-pathway pulse studies.
Choosing for a Study
Sustained exposure question: DAC. Pulsatility or synergy question: No DAC. The full secretagogue shelf lives in our Growth Hormone Secretagogue collection.
All products discussed are intended strictly for in-vitro research and laboratory use only. They are not for human or veterinary use, consumption, or therapeutic application.
